Medicult disclaims Swedish offer

The Norwegian company Medicult's Board is highly sceptical to the yesterday announced Vitrolife offer.

By Sophia Carlsson

January 15, 2009 12:00 AM

Medicult, a Norwegian

company focused on assisted reproductive technologies, announced today that its Board of Directors does not believe that the un-invited shares-for-shares offer made by Vitrolife on January 14th.

The implicit conversion

value of the MEC share is substantially below what the Medicult Board of Directors believes is a fair valuation of its shares. Specifically the offer places no value at Medicult pipeline of projects within the field of IVF products and well-defined media for stem cells applications. Furthermore, no fair value seems to be reflected of the full positive benefits of the recent acquisitions in US.

Another reason for the

scepticism is that the structure of the offer is a shares-for-shares deal. As the Board is uncertain as to the evaluation of the shares in Vitrolife it is the opinion of the Board that it should only recommend to its shareholders a deal-structure that is either all cash or with a significant cash-component.

In order to protect

the interests of Medicult and to evaluate its strategic alternatives, the Board of Directors intends to hire an investment bank as its advisor.

{{ comments.count === 1 ? '1 comment' : comments.count > 1 ? '{0} comments'.replace('{0}', comments.count) : 'Write a comment' }}

By submitting the comment you accept the terms. See terms

Good comment behavior

Keep a good tone in your comments, avoid personal attacks and posts of marketing character. Apply only link on your comment if it is relevant to the debate.

Be aware that the debates are moderated by the portal's editorial team.

The comment has been created.

Your comment will not be visible until you activate it. In a few moments you will receive an email where you must click on a link to activate your comment.